Table 3. Risk of breast cancer associated with non-aspirin NSAID use.
| Cases (n=3708) | Controls (n=20 000) | Odds ratioa (95% CI) | |
|---|---|---|---|
| Non-aspirin NSAID use | |||
| No useb | 1563 | 8398 | |
| Current use | 852 | 4465 | 0.98 (0.88, 1.09) |
| Past use | 1293 | 7137 | 0.94 (0.86, 1.03) |
| Non-aspirin NSAID duration | |||
| 0–0.9 years | 611 | 3208 | 0.98 (0.87, 1.09) |
| 1–1.9 years | 84 | 387 | 1.13 (0.87, 1.47) |
| 2–3.9 years | 64 | 357 | 0.92 (0.69, 1.23) |
| 4+ years | 93 | 513 | 0.94 (0.74, 1.21) |
| Non-aspirin NSAID dosec | |||
| Low-medium | 128 | 658 | 0.99 (0.80, 1.23) |
| High | 113 | 599 | 0.99 (0.79, 1.24) |
| Non-aspirin NSAID indicationc | |||
| OA | 207 | 1063 | 0.98 (0.82, 1.17) |
| RA | 26 | 145 | 0.96 (0.61, 1.51) |
| Other pain | 8 | 49 | 0.84 (0.38, 1.86) |
OA=osteoarthritis, RA=rheumatoid arthritis; NSAID=nonsteroidal anti-inflammatory drugs.
a
Adjusted for age, calendar year, BMI, smoking, alcohol, prior benign breast disease, paracetamol, aspirin, steroid and HRT use.
b
Reference category.
c
Among current long term users (1 or more years of treatment duration) vs non-users. Cut-off values for dose in mg were: aceclofenac 100, acemetacin 120, apazone 600, diclofenac 100, etodolac 400, fenbufen 900, fenoprofen 1200, flurbiprofen 150, ibuprofen 1200, indomethacin 75, ketoprofen 150, mefenamic 1000, meloxicam 7.5, nabumetone 1000, naproxen 750, piroxicam 10, sulindac 200, tenoxicam 10, and tiaprofenic acid 450.